-
CSR Summary
Not Yet Available
-
NCT02713282
-
Primary Citation
Not Available
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedSchizophrenia
Sponsor Protocol NumberR092670SCH3015Enrollment306Data PartnerJohnson & Johnson% Female35.4%Mean/Median Age (Years)36.5% WhiteN/A
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
- 2024-0268 : Use of machine learning for discerning prognostic and predictive features in schizophrenia disease and evaluating their generalizability
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment: An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis